Detecting familial defective apolipoprotein B-100 R3500Q in Vietnamese patients by PCR-sequencing

Bui Van Cong; Nguyen Thi Nga; Pham Nguyen Oanh Vu; Truong Kim Phuong

6 (1) 2016

Detecting familial defective apolipoprotein B-100 R3500Q in Vietnamese patients by PCR-sequencing

Author - Affiliation:

Bui Van Cong - Univerity of Science, Vietnam National University Ho Chi Minh City , Vietnam

Nguyen Thi Nga - Ho Chi Minh City Open University , Vietnam

Pham Nguyen Oanh Vu - Ho Chi Minh City Open University , Vietnam

Truong Kim Phuong - Ho Chi Minh City Open University , Vietnam

Corresponding author: Truong Kim Phuong - phuong.tk@ou.edu.vn

Abstract

Familial defective apolipoprotein B-100 (FDB) is an autosomal codominant disorder associated with hypercholesterolemia, caused by mutations in and around codon 3500 of the Apolipoprotein (Apo) B gene, which encodes Apo B-100. The first mutation occurred in Arginine codons to be described, and the most characterized, is caused by a G→A transition at nucleotide 10,708 and results in the substitution of Arginine by Glutamine at codon 3500 (ApoB R3500Q). In this study, we have identified 27 R3500Q mutations in known FDB patients using PCRSequencing method. As the result, most of the patients carried heterozygous mutation R3500Q. PCR-Sequencing method that we have applied in this study proved consistent and so easily identified mutations correctly.

Keywords

Apoliprotein B-100; familial defective; ApoB R3500Q

Full Text:

PDF

References

Brown, M. S., Goldstein, J. L. (1986). A receptor-mediated pathway for cholesterol homeostasis, Science, 232(4746), 34 - 47.

Choong, M. L., Koay, E. S., Khoo, K. L., Khaw, M. C., Sethi, S. K. (1997). Denaturing gradientgel electrophoresis screening of familial defective apolipoprotein B-100 in a mixed Asian cohort: two cases of arginine3500tryptophan mutation associated with a unique haplotype, Clin Chem., 43(6 Pt 1), 916 - 923.

Dedoussis, G. V., Genschel, J., Bochow, B., Pitsavos, C., Skoumas, J., Prassa, M., Lkhagvasuren, S., Toutouzas, P., Vogt, A., Kassner, U., Thomas, H. P., Schmidt, H. (2004). Molecular characterization of familial hypercholesterolemia in German and Greek patients, Hum Mutat., 23(3), 285 - 286.

Fisher, E., Scharnagl, H., Hoffmann, M. M., Kusterer, K., Wittmann, D., Wieland, H., Gross, W., März, W. (1999). Mutations in the apolipoprotein (apo) B-100 receptor-binding region: detection of apo B-100 (Arg3500Trp) associated with two new haplotypes and evidence that apo B-100 (Glu3405Gln) diminishes receptor-mediated uptake of LDL, Clin Chem., 45(7), 1026 - 1038.

Friedl, W., Ludwig, E. H., Balestra, M. E., Arnold, K. S., Paulweber, B., Sandhofer, F., McCarthy, B. J., Innerarity, T. L. (1991). Apolipoprotein B gene mutations in Austrian subjects with heart disease and their kindred, Arterioscler Thromb., 11(2), 371 - 378.

Futema, M., Plagnol, V., Whittall, R. A., Neil, H. A. (2012). Use of targeted exome sequencing as a diagnostic tool for Familial Hypercholesterolaemia, J Med Genet., 49(10), 644 - 649.

Futema, M., Whittall, R. A., Kiley, A., Steel, L. K., Cooper, J. A., Badmus, E., Leigh, S. E., Karpe, F., Neil, H. A., Simon Broome Register Group, Humphries, S. E. (2013). Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic, Atherosclerosis, 229(1), 161 - 168.

García-García, A. B., Real, J. T., Puig, O., Cebolla, E., Marín-García, P., Martínez Ferrandis, J. I., García-Sogo, M., Civera, M., Ascaso, J. F., Carmena, R., Armengod, M. E., Chaves, F. J. (2001). Molecular genetics of familial hypercholesterolemia in Spain: Ten novel LDLR mutations and population analysis, Hum Mutat., 18(5), 458 - 459.

Heath, K. E., Humphries, S. E., Middleton-Price, H., Boxer, M. (2001). A molecular genetic service for diagnosing individuals with familial hypercholesterolaemia (FH) in the United Kingdom, Eur J Hum Genet., 9(4), 244 - 252.

Henderson, B. G., Wenham, P. R., Ashby, J. P., Blundell, G. (1997). Detecting familial defective apolipoprotein B-100: three molecular scanning methods compared, Clin Chem., 43(9), 1630 - 1634.

Hevonoja, T., Pentikäinen, M. O., Hyvönen, M. T., Kovanen, P. T., Ala-Korpela, M. (2000). Structure of low density lipoprotein (LDL) particles: basis for understanding molecular changes in modified LDL, Biochim Biophys Acta., 1488(3), 189 - 210.

Horvath, A., Savov, A., Kirov, S., Karshelova, E., Paskaleva, I., Goudev, A., Ganev, V. (2001). High frequency of the ApoB-100 R3500Q mutation in Bulgarian hypercholesterolemia subjects, J Med Genet., 38(8), 536 - 540.

Innerarity, T. L., Mahley, R. W., Weisgraber, K. H., Bersot, T. P., Krauss, R. M., Vega, G. L. (1990) Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolaemia, J Lipid Res., 31(8), 1337 - 1349.

Marduel, M., Carrié, A., Sassolas, A., Devillers, M., Carreau, V., Di Filippo, M., Erlich, D., Abifadel, M., Marques-Pinheiro, A., Munnich, A., Junien, C.; French ADH Research Network, Boileau, C., Varret, M., Rabès, J. P. (2010). Molecular spectrum of autosomal dominant hypercholesterolemia in France, Hum Mutat., 31(11), E1811 – E1824.

Myant, N. B. (1993). Familial defective apolipoprotein B-100: including some comparisons with familial hypercholesterolaemia, Atherosclerosis., 104(1-2), 1 - 18.

Pullinger, C. R., Hennessy, L. K., Chatterton, J. E., Liu, W., Love, J. A., Mendel, C. M., Frost, P. H., Malloy, M. J., Schumaker, V. N., Kane, J. P. (1995). Familial ligand-defective apolipoprotein B. Identification of a new mutation that decreases LDL receptor binding affinity, J Clin Invest., 95(3), 1225 - 1234.

Rabès, J. P., Varret, M., Devillers, M., Aegerter, P., Villéger, L., Krempf, M., Junien, C., Boileau, C. (2000). R3531C mutation in the apolipoprotein B gene is not sufficient to cause hypercholesterolemia, Arterioscler Thromb Vasc Biol., 20(10), E76 - E82.

Real, J. T., Chaves, F. J., Ejarque, I., García-García, A. B., Valldecabres, C., Ascaso, J. F., Armengod, M. E., Carmena, R. (2003). Influence of LDL receptor gene mutations and the R3500Q mutation of the apoB gene on lipoprotein phenotype of familial hypercholesterolemic patients from a South European population, Eur J Hum Genet., 11(12), 959 - 965.

Tai, D. Y., Pan, J. P., Lee-Chen, G. J. (1998). Identification and haplotype analysis of apolipoprotein B-100 Arg3500-->Trp mutation in hyperlipidemic Chinese, Clin Chem., 44(8 Pt 1), 1659 - 1665.

Tai, E. S., Koay, E. S., Chan, E., Seng, T. J., Loh, L. M., Sethi, S. K., Tan, C. E. (2001). Compound heterozygous familial hypercholesterolemia and familial defective apolipoprotein B-100 produce exaggerated hypercholesterolemia, Clin Chem., 47(3), 438 - 443.

Thiart, R., Scholtz, C. L., Vergotine, J., Hoogendijk, C. F., de Villiers, J. N., Nissen, H., Brusgaard, K., Gaffney, D., Hoffs, M. S., Vermaak, W. J., Kotze, M. J. (2000). Predominance of a 6 bp deletion in exon 2 of the LDL receptor gene in Africans with familial hypercholesterolaemia, J Med Genet., 37(7), 514 - 519.

Thomas, E. R., Atanur, S. S., Norsworthy, P. J., Encheva, V., Snijders, A. P., Game, L., Vandrovcova, J., Siddiq, A., Seed, M., Soutar, A. K., Aitman, T. J. 1. (2013). Identification and biochemical analysis of a novel APOB mutation that causes autosomal dominant hypercholesterolemia, Mol Genet Genomic Med., 1(3), 155 - 161.

Tybjærg-Hansen, A., Humphries, S. E. (1992). Familial defective apolipoprotein B-100: a single mutation that causes hypercholesterolaemia and premature coronary artery disease, Atherosclerosis., 96(2-3), 91 - 107.

Tybjaerg-Hansen, A., Steffensen, R., Meinertz, H., Schnohr, P., Nordestgaard, B. G. (1998). Association of mutations in the apolipoprotein B gene with hypercholesterolemia and the risk of ischemic heart disease, N Engl J Med., 338(22), 1577 - 1584.

Wang, J., Ban, M. R., Hegele, R. A. (2005). Multiplex ligation-dependent probe amplification of LDLR enhances molecular diagnosis of familial hypercholesterolemia, J Lipid Res., 46(2), 366 - 372.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.